Related Experiment Video
Updated: Jun 13, 2025
Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
Published on: May 28, 2014
Azolato-Bridged Dinuclear Platinum(II) Complexes Exhibit Androgen Receptor-Mediated Anti-Prostate Cancer Activity
Tasuku Arai1,2, Masashi Oshima1,3,4, Masako Uemura5
1Laboratory of Biochemistry, Department of Bioscience and Engineering, College of Systems Engineering and Science, Shibaura Institute of Technology, Saitama, Saitama 337-8570, Japan.
Abstract:
Prostate cancer is an androgen-dependent malignancy that presents a marked treatment challenge, particularly after progression to the castration-resistant stage. Traditional treatments such as androgen deprivation therapy often lead to resistance, necessitating novel therapeutic approaches. Previous studies have indicated that some of the azolato-bridged dinuclear platinum(II) complexes (general formula: [{cis-Pt(NH3)2}2(μ-OH)(μ-azolato)]X2, where azolato = pyrazolato, 1,2,3-triazolato, or tetrazolato and X = nitrate or perchlorate) inhibit androgen receptor (AR) signaling. Therefore, here we investigated the potential of 14 such complexes as agents for the treatment of prostate cancer by examining their antiproliferative activity in the human prostate adenocarcinoma cell line LNCaP. Several of the complexes, particularly 5-H-Y ([{cis-Pt(NH3)2}2(μ-OH)(μ-tetrazolato-N2,N3)](ClO4)2), effectively inhibited LNCaP cell growth, even at low concentrations, by direct modulation of AR signaling, and by binding to DNA and inducing apoptosis, which is a common mechanism of action of Pt-based drugs such as cisplatin (cis-diamminedichloridoplatinum(II)). Comparative analysis with cisplatin revealed superior inhibitory effects of these complexes. Further investigation revealed that 5-H-Y suppressed mRNA expression of genes downstream from AR and induced apoptosis, particularly in cells overexpressing AR, highlighting its potential as an AR antagonist. Thus, we provide here insights into the mechanisms underlying the antiproliferative effects of azolato-bridged complexes in prostate cancer.
Insights
New platinum(II) complexes show promise in treating prostate cancer by inhibiting androgen receptor (AR) signaling and inducing apoptosis. These novel compounds, particularly 5-H-Y, offer a potential new therapeutic avenue for castration-resistant prostate cancer.
Area of Science:
- Medicinal Chemistry
- Oncology
- Molecular Biology
Background:
- Prostate cancer is an androgen-dependent malignancy with treatment challenges, especially in castration-resistant stages.
- Current therapies like androgen deprivation therapy (ADT) can lead to resistance, necessitating novel treatment strategies.
- Azolato-bridged dinuclear platinum(II) complexes have shown potential in inhibiting androgen receptor (AR) signaling.
Purpose of the Study:
- To investigate the antiproliferative activity of 14 azolato-bridged dinuclear platinum(II) complexes against prostate cancer.
- To evaluate the potential of these complexes as novel agents for prostate cancer treatment, particularly those resistant to ADT.
- To elucidate the mechanism of action of effective platinum(II) complexes in prostate cancer cells.
Main Methods:
- Synthesis and characterization of 14 azolato-bridged dinuclear platinum(II) complexes.
- Assessment of antiproliferative activity using the LNCaP human prostate adenocarcinoma cell line.
- Analysis of androgen receptor (AR) signaling modulation, DNA binding, apoptosis induction, and gene expression.
Main Results:
- Several platinum(II) complexes, notably 5-H-Y, demonstrated significant antiproliferative effects on LNCaP cells, even at low concentrations.
- Complex 5-H-Y directly modulated AR signaling and induced apoptosis, similar to cisplatin but with superior efficacy.
- 5-H-Y suppressed AR downstream gene expression and enhanced apoptosis in AR-overexpressing cells, confirming its role as an AR antagonist.
Conclusions:
- Azolato-bridged dinuclear platinum(II) complexes, especially 5-H-Y, are effective antiproliferative agents against prostate cancer cells.
- These complexes exhibit a dual mechanism of action involving AR signaling inhibition and DNA-based cytotoxicity, leading to apoptosis.
- Complex 5-H-Y shows significant potential as a novel therapeutic agent for prostate cancer, including castration-resistant forms.
More Related Videos
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
10:36In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues
Published on: March 21, 2017
Related Concept Videos
01:31Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
01:17Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
01:28Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
01:22Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:16Adrenergic Agonists: Chemistry and Structure-Activity Relationship
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...